CBTN Partners with Day One to Drive New Therapies for Pediatric Brain Tumors | PR Newswire [Video]

, /PRNewswire/ — The Children’s Brain Tumor Network (CBTN), a consortium of leading pediatric brain tumor research institutions, announces that it has formed a groundbreaking partnership with Day One Biopharmaceuticals (Day One), a company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. This new partnership between CBTN and Day One aims to accelerate the development of new treatments for children with brain tumors. It leverages the robust Pediatric Brain Tumor Atlas (PBTA), a comprehensive resource containing genomic, clinical, and imaging data from over 7,600 pediatric brain tumor patients. Day One will utilize this data set to design clinical trials.

Together, CBTN and Day One aim to accelerate the development of new treatments for children with brain tumors.

“We are deeply grateful for this partnership, which reflects a shared commitment to advancing therapies for children with brain tumors,” said Dr. Angela Waanders, LLG Study Chair …